JPH09503394A - 改良されたdnアーゼ液体溶液 - Google Patents
改良されたdnアーゼ液体溶液Info
- Publication number
- JPH09503394A JPH09503394A JP7522968A JP52296895A JPH09503394A JP H09503394 A JPH09503394 A JP H09503394A JP 7522968 A JP7522968 A JP 7522968A JP 52296895 A JP52296895 A JP 52296895A JP H09503394 A JPH09503394 A JP H09503394A
- Authority
- JP
- Japan
- Prior art keywords
- solution
- dnase
- rhdnase
- calcium
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Jellies, Jams, And Syrups (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.約1 mMから約1 M のカルシウムカチオンを生物学的に活性な主成分としての DNアーゼを含む液体溶液中に使用することを含む、前記溶液中でDNアーゼの熱凝 集を最小限にする方法。 2.約50 mg/mlから約200 mg/ml の糖を生物学的に活性な主成分としてのDNアー ゼを含む液体溶液中に使用することを含む、前記溶液中でDNアーゼの熱凝集を最 小限にする方法。 3.前記溶液を噴霧乾燥し、噴霧乾燥生成物を、個体の肺に投与すると治療的に 有効な吸引可能なDNアーゼ含有粉末として回収する段階をさらに含む請求項1ま たは2に記載の方法。 4.DNアーゼとDNアーゼ凝集を最小限にする量のカルシウムカチオンを含む、生 物学的に活性な主成分としての前記DNアーゼの熱凝集に対して保護された液体溶 液。 5.DNアーゼとDNアーゼ凝集を最小限にする量の糖を含む、生物学的に活性な主 成分としての前記DNアーゼの熱凝集に対して保護された液体溶液。 6.カルシウムカチオンが約1 mM〜約1 M の濃度である請求項4に記載の溶液。 7.糖が約50 mg/ml〜約200 mg/ml の濃度である請求項5に記載の溶液。 8.カルシウムカチオンが、約10 mM 〜約100 mMの塩化カルシウムを溶液に添加 することにより与えられる請求項4に記載の溶液。 9.生物学的に活性な主成分としてのDNアーゼを含む中性未満のpHの液体溶液中 で約1 mM〜約1 M のカルシウムカチオンを使用することを含む前記溶液を安定化 する方法。 10.安定化がタンパク質の沈殿の減少により表される請求項9に記載の方法。 11.安定化がDNアーゼの脱アミド化の阻害により表される請求項9に記載の方法 。 12.溶液のpHが約5である請求項9に記載の方法。 13.カルシウムカチオンが塩化カルシウムにより与えられる請求項1または9に 記載の方法。 14.カルシウムカチオンが、約10 mM〜約100 mMの塩化カルシウムを溶液中で使 用することにより与えられる請求項1または9に記載の溶液。 15.生物学的に活性な主成分としてのDNアーゼと安定化量のカルシウムイオンを 含む、中性未満のpHを有する安定化された液体溶液。 16.約5のpHを有する請求項15に記載の溶液。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20650494A | 1994-03-04 | 1994-03-04 | |
US08/206,504 | 1994-03-04 | ||
US37752795A | 1995-01-20 | 1995-01-20 | |
US206,504 | 1995-01-20 | ||
US377,527 | 1995-01-20 | ||
US08/377,527 | 1995-01-20 | ||
PCT/US1995/002457 WO1995023854A1 (en) | 1994-03-04 | 1995-02-28 | IMPROVED DNase LIQUID SOLUTIONS |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09503394A true JPH09503394A (ja) | 1997-04-08 |
JP3009224B2 JP3009224B2 (ja) | 2000-02-14 |
Family
ID=26901408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7522968A Expired - Lifetime JP3009224B2 (ja) | 1994-03-04 | 1995-02-28 | 改良されたdnアーゼ液体溶液 |
Country Status (7)
Country | Link |
---|---|
US (2) | US6383788B1 (ja) |
EP (1) | EP0748377B1 (ja) |
JP (1) | JP3009224B2 (ja) |
AT (1) | ATE401394T1 (ja) |
CA (1) | CA2184581C (ja) |
DE (1) | DE69535787D1 (ja) |
WO (1) | WO1995023854A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE401394T1 (de) * | 1994-03-04 | 2008-08-15 | Genentech Inc | Verbesserte dnase flüssige lösungen |
EP0938543A4 (en) * | 1996-09-04 | 2002-10-29 | Nexell Therapeutics Inc | COMPOSITIONS CONTAINING NUCLEASE AND CHELATE IMPROVERS TO IMPROVE CELL RECOVERY IN CELL SEPARATION PROCESSES |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
ES2332402T5 (es) | 2000-10-12 | 2018-05-14 | Genentech, Inc. | Formulaciones de proteína concentradas de viscosidad reducida |
SG174258A1 (en) | 2009-03-06 | 2011-10-28 | Genentech Inc | Antibody formulation |
ES2919136T3 (es) | 2010-08-11 | 2022-07-22 | Ironwood Pharmaceuticals Inc | Formulaciones estables de linaclotida |
JP6071018B2 (ja) | 2014-10-31 | 2017-02-01 | Jcrファーマ株式会社 | 組換えヒトDNaseIの製造方法 |
NZ733912A (en) * | 2015-01-04 | 2023-04-28 | Protalix Ltd | Modified dnase and uses thereof |
WO2017049205A2 (en) * | 2015-09-18 | 2017-03-23 | Amunix Operating Inc. | Growth hormone formulation |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3042587A (en) * | 1960-11-29 | 1962-07-03 | Merck & Co Inc | Stabilized desoxyribonuclease preparation |
CA1059937A (en) | 1975-03-25 | 1979-08-07 | Boen T. Khouw | Isolation and purification of deoxyribonuclease |
US4233405A (en) * | 1979-10-10 | 1980-11-11 | Rohm And Haas Company | Process for spray drying enzymes |
ATE358176T1 (de) | 1988-12-23 | 2007-04-15 | Genentech Inc | Menschliche dnase |
US5279823A (en) * | 1992-06-08 | 1994-01-18 | Genentech, Inc. | Purified forms of DNASE |
ATE401394T1 (de) * | 1994-03-04 | 2008-08-15 | Genentech Inc | Verbesserte dnase flüssige lösungen |
US5580856A (en) * | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
-
1995
- 1995-02-28 AT AT95911123T patent/ATE401394T1/de not_active IP Right Cessation
- 1995-02-28 JP JP7522968A patent/JP3009224B2/ja not_active Expired - Lifetime
- 1995-02-28 WO PCT/US1995/002457 patent/WO1995023854A1/en active Application Filing
- 1995-02-28 EP EP95911123A patent/EP0748377B1/en not_active Expired - Lifetime
- 1995-02-28 CA CA002184581A patent/CA2184581C/en not_active Expired - Lifetime
- 1995-02-28 DE DE69535787T patent/DE69535787D1/de not_active Expired - Fee Related
- 1995-02-28 US US08/696,955 patent/US6383788B1/en not_active Expired - Lifetime
-
2002
- 2002-02-12 US US10/076,213 patent/US7018825B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0748377B1 (en) | 2008-07-16 |
EP0748377A1 (en) | 1996-12-18 |
US20030054532A1 (en) | 2003-03-20 |
US7018825B2 (en) | 2006-03-28 |
CA2184581C (en) | 2005-02-22 |
DE69535787D1 (de) | 2008-08-28 |
ATE401394T1 (de) | 2008-08-15 |
US6383788B1 (en) | 2002-05-07 |
JP3009224B2 (ja) | 2000-02-14 |
WO1995023854A1 (en) | 1995-09-08 |
CA2184581A1 (en) | 1995-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012326171B2 (en) | Etanercept formulations stabilized with sodium chloride | |
TWI593421B (zh) | 凍乾的重組vwf調配物 | |
US10071136B2 (en) | Stable liquid formulations of recombinant fusion proteins | |
JP2986215B2 (ja) | Dnアーゼ含有医薬製剤 | |
US10293045B2 (en) | Stable liquid formulations of recombinant fusion proteins | |
WO2011163652A2 (en) | Treatment of sanfilippo syndrome type b | |
AU2016204793B2 (en) | Modified DNase and uses thereof | |
AU738413B2 (en) | Human growth hormone-containing aqueous pharmaceutical composition | |
JPS62164632A (ja) | 安定化されたヒト組織プラスミノゲン活性化因子組成物 | |
JP3009224B2 (ja) | 改良されたdnアーゼ液体溶液 | |
JP2001518915A (ja) | インシュリンと吸収増強剤の共沈殿による治療用粉末の調整法 | |
KR20180124120A (ko) | 재조합 산 알파-글루코시다제를 포함하는 제형 | |
BR112012010392B1 (pt) | composição e kit para o inibidor de alfa-1 proteinase | |
CA1214102A (en) | Pharmaceutical preparation containing purified fibronectin | |
EP3394095B1 (en) | Collagen 7 compositions and methods of using the same | |
AU2020311050A1 (en) | Stable formulations of recombinant proteins | |
JP3895782B2 (ja) | コンドロイチナーゼ組成物およびそれを含有する注射用製剤 | |
EP0419251B1 (en) | Protein-containing aqueous solutions | |
CN113144174B (zh) | 治疗高尿酸相关性疾病的药物 | |
EP3988122A1 (en) | Application of transthyretin in entering eye and preparing drop | |
JPH0767642A (ja) | 酵素組成物 | |
WO2024117070A1 (ja) | ナフタレン誘導体の眼科疾患用治療薬 | |
JP2001526292A (ja) | クエン酸またはトリエタノールアミンおよびそれらの組合せを含むdna医薬製剤 | |
AU619697B2 (en) | Thrombolytic composition containing tissue type plasminogen activator or derivative thereof | |
KR20120083308A (ko) | 해소 억제효과를 가지는 혈장 단백질 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071203 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081203 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091203 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101203 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101203 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111203 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111203 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121203 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121203 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131203 Year of fee payment: 14 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |